Caprock Group LLC Purchases Shares of 10,070 Stryker Corporation $SYK

Caprock Group LLC acquired a new position in shares of Stryker Corporation (NYSE:SYK) in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm acquired 10,070 shares of the medical technology company’s stock, valued at approximately $3,942,000.

A number of other institutional investors also recently modified their holdings of SYK. Norges Bank bought a new stake in Stryker in the second quarter valued at $1,882,173,000. Alliancebernstein L.P. grew its stake in shares of Stryker by 307.6% in the 2nd quarter. Alliancebernstein L.P. now owns 5,596,508 shares of the medical technology company’s stock valued at $2,214,146,000 after buying an additional 4,223,366 shares during the period. Corient Private Wealth LLC increased its position in Stryker by 104.4% in the 2nd quarter. Corient Private Wealth LLC now owns 2,245,841 shares of the medical technology company’s stock valued at $887,525,000 after buying an additional 1,146,998 shares in the last quarter. ABN AMRO Bank N.V. acquired a new position in Stryker during the 2nd quarter worth approximately $191,047,000. Finally, Vanguard Group Inc. boosted its holdings in Stryker by 1.3% in the second quarter. Vanguard Group Inc. now owns 33,500,571 shares of the medical technology company’s stock worth $13,253,831,000 after acquiring an additional 440,607 shares in the last quarter. Institutional investors and hedge funds own 77.09% of the company’s stock.

Wall Street Analyst Weigh In

A number of brokerages have recently weighed in on SYK. Royal Bank Of Canada reaffirmed an “outperform” rating and set a $435.00 target price on shares of Stryker in a research report on Friday, November 14th. Wall Street Zen downgraded shares of Stryker from a “buy” rating to a “hold” rating in a report on Saturday, January 31st. BTIG Research raised their price objective on shares of Stryker from $410.00 to $412.00 and gave the company a “buy” rating in a research note on Friday, January 30th. Barclays reissued an “overweight” rating and set a $469.00 target price on shares of Stryker in a research report on Monday, February 2nd. Finally, Wells Fargo & Company raised their price target on shares of Stryker from $452.00 to $456.00 and gave the company an “overweight” rating in a research report on Friday, November 14th. Twelve research analysts have rated the stock with a Buy rating and five have assigned a Hold rating to the company’s stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $426.94.

Insider Buying and Selling at Stryker

In other news, CAO William E. Berry, Jr. sold 1,953 shares of the stock in a transaction that occurred on Friday, November 14th. The shares were sold at an average price of $365.49, for a total transaction of $713,801.97. Following the completion of the transaction, the chief accounting officer directly owned 2,833 shares of the company’s stock, valued at $1,035,433.17. This represents a 40.81% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Ronda E. Stryker sold 250,000 shares of Stryker stock in a transaction that occurred on Wednesday, February 4th. The stock was sold at an average price of $362.92, for a total transaction of $90,730,000.00. Following the completion of the sale, the director directly owned 2,457,331 shares in the company, valued at $891,814,566.52. This trade represents a 9.23% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold a total of 252,118 shares of company stock worth $91,504,172 over the last three months. 5.90% of the stock is currently owned by insiders.

Stryker Stock Performance

Shares of SYK opened at $363.76 on Thursday. The stock has a 50 day moving average of $357.92 and a 200 day moving average of $369.84. The company has a market capitalization of $139.11 billion, a price-to-earnings ratio of 43.30, a PEG ratio of 2.11 and a beta of 0.87. Stryker Corporation has a 12 month low of $329.16 and a 12 month high of $404.87. The company has a current ratio of 1.89, a quick ratio of 1.21 and a debt-to-equity ratio of 0.66.

Stryker (NYSE:SYK) last announced its quarterly earnings data on Thursday, January 29th. The medical technology company reported $4.47 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $4.40 by $0.07. Stryker had a return on equity of 24.41% and a net margin of 12.92%.The firm had revenue of $7.17 billion during the quarter, compared to the consensus estimate of $7.12 billion. During the same quarter in the prior year, the company earned $4.01 EPS. The business’s revenue for the quarter was up 11.4% on a year-over-year basis. As a group, sell-side analysts forecast that Stryker Corporation will post 13.47 earnings per share for the current year.

Stryker Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Thursday, April 30th. Shareholders of record on Tuesday, March 31st will be given a $0.88 dividend. The ex-dividend date of this dividend is Tuesday, March 31st. This represents a $3.52 annualized dividend and a yield of 1.0%. Stryker’s payout ratio is currently 41.90%.

Stryker Company Profile

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons’ offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.